Therapeutics Acquisition Corp. | Business Contracts

Purchase Agreement dated September 13, 2022 by and among the Company, Piper Sandler & Co. and Guggenheim Securities, LLC (Filed With SEC on September 14, 2022)

Fourth Amendment dated May 6, 2022 to Exclusive Sublicense Agreement dated April 2, 2020 (Filed With SEC on August 12, 2022)

Consulting Agreement effective January 1, 2022 by and between POINT Biopharma Inc. and Dr. Neil Fleshner (Filed With SEC on March 25, 2022)

Form of Indemnification Agreement (Filed With SEC on July 1, 2021)

Exclusive License and Commercialization Agreement, dated December 16, 2020, by and between POINT Biopharma Inc., Canadian Molecular Probe Consortium, the Centre for Probe... (Filed With SEC on March 23, 2021)

Sublicense Agreement dated November 14, 2019 between POINT Theranostics Inc. and Scintomics GmbH (Filed With SEC on March 25, 2022)

Employment Agreement effective December 1, 2021, as amended, by and between POINT Biopharma USA Inc. and Justyna Kelly (Filed With SEC on March 25, 2022)

Description of Securities (Filed With SEC on March 25, 2022)

Revised Form of Non (Filed With SEC on December 10, 2021)

Revised Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Filed With SEC on December 10, 2021)

Revised Form of (Filed With SEC on December 10, 2021)

Third Amendment to Exclusive Sublicense Agreement, dated September 24, 2021, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 to be effective as of December 31, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Exclusive Sublicense Agreement, dated April 2, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Directors) (Filed With SEC on July 1, 2021)

Amended and Restated Registration and Stockholder Rights Agreement, dated June 30, 2021, by and among Therapeutics Acquisition Holdings LLC and the stockholders party thereto (Filed With SEC on July 1, 2021)

POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Filed With SEC on July 1, 2021)

Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (Filed With SEC on July 1, 2021)

Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (Filed With SEC on July 1, 2021)

Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Directors) (Filed With SEC on July 1, 2021)

Form of Incentive Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Filed With SEC on July 1, 2021)

Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma USA Inc. and Todd Hockemeyer (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of March 9, 2021, by and between POINT Biopharma Corp. and Donna Husack (Filed With SEC on March 23, 2021)

Loan and Security Agreement, dated as of July 10, 2020, by and between West 78th Street, LLC and CIBC Bank USA (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Ari Shomair, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of November 2, 2020, by and between POINT Biopharma Corp. and Justyna Kelly, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of July 19, 2020, by and between POINT Biopharma USA Inc. and Jessica Jensen (Filed With SEC on March 23, 2021)

Consulting Agreement by and between POINT Biopharma Inc. and Dr. Neil Fleshner, dated February 22, 2021 (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of July 24, 2020, by and between POINT Biopharma Corp. and William Demers, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Joe McCann, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Allan Silber, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

2020 POINT Biopharma, Inc. Equity Incentive Plan (Filed With SEC on March 23, 2021)

Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Michael Gottlieb, as amended March 8, 2021 (Filed With SEC on March 23, 2021)

Description of the Companys securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 4, 2021)

Letter Agreement, dated July 7, 2020, by and among the Company, its officers, its directors and Therapeutics Acquisition Holdings, LLC (Filed With SEC on July 10, 2020)

Underwriting Agreement, dated July 7, 2020, by and among the Company and Jefferies LLC (Filed With SEC on July 10, 2020)

Investment Management Trust Agreement, dated July 7, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as trustee (Filed With SEC on July 10, 2020)

Registration and Stockholder Rights Agreement, dated July 7, 2020, by and among the Company, Therapeutics Acquisition Holdings, LLC and the other holders party thereto (Filed With SEC on July 10, 2020)

Private Placement Class A Common Stock Purchase Agreement, dated July 7, 2020 by and among the Company and Therapeutics Acquisition Holdings, LLC (Filed With SEC on July 10, 2020)

Private Placement Class A Common Stock Purchase Agreement, dated July 8, 2020 by and among the Company and Therapeutics Acquisition Holdings, LLC (Filed With SEC on July 10, 2020)

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant (Filed With SEC on July 6, 2020)

Form of Registration and Stockholder Rights Agreement among the Registrant and the Holders of the Founder Shares and Private Placement Shares (Filed With SEC on July 6, 2020)

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant (Filed With SEC on July 6, 2020)

Form of Private Placement Class A Common Stock Purchase Agreement between the Registrant and our Sponsor (Filed With SEC on July 6, 2020)

Form of Underwriting Agreement (Filed With SEC on July 6, 2020)

Form of Underwriting Agreement (Filed With SEC on June 15, 2020)

Specimen Unit Certificate (Filed With SEC on June 15, 2020)

Specimen Common Stock Certificate (Filed With SEC on June 15, 2020)

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant (Filed With SEC on June 15, 2020)

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant (Filed With SEC on June 15, 2020)

Form of Registration and Stockholder Rights Agreement among the Registrant and the Sponsor (Filed With SEC on June 15, 2020)

Form of Indemnity Agreement (Filed With SEC on June 15, 2020)

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant (Filed With SEC on June 15, 2020)

Form of Subscription Agreement between the Registrant and our Sponsor (Filed With SEC on June 15, 2020)

Form of Private Placemenet Warrants Purchase Agreement between the Registrant and our Sponsor (Filed With SEC on June 15, 2020)

Specimen Warrant Certificate (Filed With SEC on June 15, 2020)

Therapeutics Acquisition Corp. (57)